Sugi Predict

Sugi Predict / Compounds / SCHEMBL40057

SCHEMBL40057

SCHEMBL40057

CC(C)(C)OC(=O)N1CCCC(C(=O)O)C1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ HPGD P15428 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.55
▸ EPHX1 P07099 1/20 0.49
▸ HSD11B1 P28845 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ USP30 Q70CQ3 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ PREP P48147 1/20 0.43
▸ GLS O94925 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181768 1.00 MEN1 (0.64) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL40056 1.00 MEN1 (0.64) MEN1ALDH1A1MAPTKMT2AHPGD
Hydrazine SCHEMBL27951659 0.97 MEN1 (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL18391126 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL30769887 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31421106 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL1439980 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL3919651 0.94 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL27963722 0.94 HPGD (0.65) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL42957 0.90 HPGD (0.62) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286583-B Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2024-01-30 — — CN claimed
CN-115286583-A Diphenylaminopyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2022-11-04 — — CN claimed
CN-106986789-B Hydroquinone compound and preparation method thereof and the application in antitumor or immunological regulation 中国人民解放军军事医学科学院生物医学分析中心 2019-07-16 — — CN claimed
CN-109251164-A A kind of synthetic method of preclamol intermediate 中山大学 2019-01-22 — — CN claimed
CN-107163023-A A kind of preparation method of 5 Bromopyrimidine compound 湖南华腾制药有限公司 2017-09-15 — — CN claimed
CN-104744549-B Betulic acid derivant and preparation method thereof and the application in antitumor drug is prepared 华东师范大学 2017-03-29 — — CN claimed
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 — — WO claimed
CN-103772477-B Glycyrrhetinic acid derivative shown in formula (I), preparation method thereof and application UNIV EAST CHINA NORMAL 2015-07-08 — — CN claimed
CN-104744549-A Betulinic acid derivative as well as preparation method and application thereof in preparing antineoplastic drugs UNIV EAST CHINA NORMAL 2015-07-01 — — CN claimed
CN-104497095-A Epandrosterone and dehydroepiandrosterone derivatives, preparation method thereof, and applications of derivatives in preparation of drugs used for preventing breast cancer UNIV EAST CHINA NORMAL 2015-04-08 — — CN claimed
CN-104292213-A Preparation method of pyrimidine derivative Hunan huateng pharmaceutical co ltd 2015-01-21 — — CN claimed
CN-103772477-A Glycyrrhetinic acid derivative shown in formula (I), preparation method thereof and application UNIV EAST CHINA NORMAL 2014-05-07 — — CN claimed
EP-4748838-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-27 — — EP disclosed
US-12630527-B2 Broad spectrum anti-cancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-19 — — US disclosed
US-12630556-B2 Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors DART NEUROSCIENCE LLC (US) 2026-05-19 — — US disclosed
CN-120058591-B Arylpiperidine compound and preparation method thereof 贵州大学 2026-05-15 — — CN disclosed
US-5064814-A Anti-thrombotic peptide and pseudopeptide derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-11-12 — — US disclosed
US-5051405-A Modified dipeptides and tripeptides as anticoagulants RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-09-24 — — US disclosed
EP-0445796-A2 Derivatives of acetic acid F. HOFFMANN-LA ROCHE AG (CH) 1991-09-11 — — EP disclosed
WO-1991005562-A1 ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630527-B2 Broad spectrum anti-cancer compounds YTHDF3, YTHDF1, YTHDF2 MEN1 3309/4885ALDH1A1 4643/4885MAPT 1684/4885
US-12630556-B2 Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors PDE1A, PDE12, PDE1B MEN1 2600/4885ALDH1A1 1599/4885MAPT 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.